Adaptimmune Therapeutics (ADAP) Earnings Date, Estimates & Call Transcripts $0.08 -0.01 (-6.63%) Closing price 04:00 PM EasternExtended Trading$0.08 +0.00 (+2.97%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Adaptimmune Therapeutics Earnings Summary Adaptimmune Therapeutics issued Q1 2025 earnings on May 13, 2025, reporting an EPS of -$0.18, which hit the consensus estimate of -$0.18. Quarterly revenue was reported to be $7.29 million, above analysts' expectations of $6.55 million. With a trailing EPS of -$0.27, Adaptimmune Therapeutics' earnings are expected to decrease next year, from ($0.14) to ($0.48) per share. Upcoming Q2 Earnings DateAug. 11Before Market OpensEstimatedConsensus EPS (May. 13) -$0.18 Actual EPS (May. 13) -$0.18 Actual Revenue (May. 13) $7.29MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)ADAP Upcoming EarningsAdaptimmune Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2025 Earnings ReportPowered by Get Adaptimmune Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptimmune Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataADAP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ADAP Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Adaptimmune Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.23-$0.10-$0.17Q2 20253-$0.18-$0.03-$0.11Q3 20253-$0.10-$0.02-$0.06Q4 20253-$0.12$0.00-$0.06 FY 2025 12 -$0.63 -$0.15 -$0.40 Q1 20261-$0.12-$0.12-$0.12Q2 20261-$0.12-$0.12-$0.12Q3 20261-$0.12-$0.12-$0.12Q4 20261-$0.12-$0.12-$0.12 Adaptimmune Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/11/2025(Estimated)-------5/13/2025Q1 2025-$0.18-$0.18--$0.18$6.55M$7.29M3/24/2025Q4 2024-$0.17-$0.26 -$0.09-$0.29$16.56M$3.22M8/12/2024Q2 2024-$0.27-$0.27$58.00M$128.23M5/15/2024Q1 2024-$0.16-$0.18 -$0.02-$0.18$4.40M$5.68M3/6/2024Q4 2023-$0.12-$0.24 -$0.12-$0.24$4.80M$0.23M11/8/2023Q3 2023-$0.20-$0.20--$0.20$5.00M$7.32M8/9/2023Q2 2023-$0.17-$0.21 -$0.04-$0.30$5.00M$5.13M Adaptimmune Therapeutics Earnings - Frequently Asked Questions When is Adaptimmune Therapeutics' earnings date? Adaptimmune Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 11th, 2025 based off last year's report dates. Learn more on ADAP's earnings history. Did Adaptimmune Therapeutics beat their earnings estimates last quarter? In the previous quarter, Adaptimmune Therapeutics (NASDAQ:ADAP) reported ($0.18) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.18). Learn more on analysts' earnings estimate vs. ADAP's actual earnings. How can I listen to Adaptimmune Therapeutics' earnings conference call? The conference call for Adaptimmune Therapeutics' latest earnings report can be listened to online. Listen to Conference Call How can I read Adaptimmune Therapeutics' conference call transcript? The conference call transcript for Adaptimmune Therapeutics' latest earnings report can be read online. Read Transcript How much revenue does Adaptimmune Therapeutics generate each year? Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded annual revenue of $178.03 million. How much profit does Adaptimmune Therapeutics generate each year? Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded net income of -$70.81 million. ADAP has generated -$0.27 earnings per share over the last four quarters. What is Adaptimmune Therapeutics' EPS forecast for next year? Adaptimmune Therapeutics' earnings are expected to decrease from ($0.14) per share to ($0.48) per share in the next year. More Earnings Resources from MarketBeat Related Companies VXRT Earnings EXOZ Earnings MGX Earnings ELUT Earnings BYSI Earnings EPIX Earnings ANRO Earnings WHWK Earnings ABOS Earnings IGMS Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Airbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a Rally This page (NASDAQ:ADAP) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
